ATE382040T1 - Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren - Google Patents

Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren

Info

Publication number
ATE382040T1
ATE382040T1 AT03750801T AT03750801T ATE382040T1 AT E382040 T1 ATE382040 T1 AT E382040T1 AT 03750801 T AT03750801 T AT 03750801T AT 03750801 T AT03750801 T AT 03750801T AT E382040 T1 ATE382040 T1 AT E382040T1
Authority
AT
Austria
Prior art keywords
beta
amyloid inhibitors
acylaminothiazole derivatives
acylaminothiazole
derivatives
Prior art date
Application number
AT03750801T
Other languages
English (en)
Inventor
Sylvie Baltzer
Bruno Schoentjes
Dorsselaer Viviane Van
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE382040T1 publication Critical patent/ATE382040T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT03750801T 2002-07-17 2003-07-11 Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren ATE382040T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0209061A FR2842523A1 (fr) 2002-07-17 2002-07-17 Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ATE382040T1 true ATE382040T1 (de) 2008-01-15

Family

ID=29797510

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03750801T ATE382040T1 (de) 2002-07-17 2003-07-11 Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren

Country Status (14)

Country Link
US (2) US7291636B2 (de)
EP (1) EP1525193B1 (de)
JP (1) JP4680593B2 (de)
AR (1) AR040570A1 (de)
AT (1) ATE382040T1 (de)
AU (1) AU2003269018A1 (de)
CY (1) CY1107903T1 (de)
DE (1) DE60318317T2 (de)
DK (1) DK1525193T3 (de)
ES (1) ES2297198T3 (de)
FR (1) FR2842523A1 (de)
PT (1) PT1525193E (de)
TW (1) TWI313680B (de)
WO (1) WO2004009565A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
CA2501803A1 (en) * 2002-10-09 2004-04-22 Pfizer Products Inc. Thiazole compounds for the treatment of neurodegenerative disorders
BRPI0418082B8 (pt) * 2003-12-26 2021-05-25 Kyowa Hakko Kirin Co Ltd derivados de tiazol úteis como antagonistas de receptor de adenosina a2a
FR2865206B1 (fr) * 2004-01-16 2009-02-06 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2873370B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
WO2005073202A1 (fr) * 2004-01-16 2005-08-11 Sanofi-Aventis Derives d’acylaminothiazole et leur application comme inhibiteurs de beta-amyloide
JP2007517840A (ja) * 2004-01-16 2007-07-05 サノフイ−アベンテイス アシルアミノチアゾール誘導体、それらの調製方法及び治療における該誘導体の使用
US7384968B2 (en) * 2004-04-01 2008-06-10 Pfizer Inc. Thiazole-amine compounds for the treatment of neurodegenerative disorders
US20050222227A1 (en) * 2004-04-01 2005-10-06 Pfizer Inc Oxazole-amine compounds for the treatment of neurodegenerative disorders
ES2309778T3 (es) * 2004-08-03 2008-12-16 Chiesi Farmaceutici S.P.A. Derivados de acidos 1-fenilalcanocarboxilicos para el tratamiento de enfermedades neurodegenerativas.
EP1981884B1 (de) * 2006-01-18 2012-06-13 Amgen, Inc Thiazolverbindungen als proteinkinase b (pkb)-inhibitoren
WO2007116901A1 (ja) * 2006-04-05 2007-10-18 Banyu Pharmaceutical Co., Ltd. 新規アリールアミド誘導体
CN100415709C (zh) * 2006-05-15 2008-09-03 西北大学 β-(3,4-二羟基苯基)-α-羟基丙酸冰片酯、其合成方法和用途
DE102006048042A1 (de) * 2006-10-11 2008-04-17 Bayer Healthcare Ag Acylaminoimidazole und Acylaminothiazole
WO2009011871A2 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
WO2009011880A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
BRPI0920183A2 (pt) * 2008-10-14 2018-05-22 Actelion Pharmaceuticals Ltd derivados de fenetilamida e seus analogos heterociclicos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3796800A (en) * 1971-11-22 1974-03-12 Uniroyal Inc Anti-inflammatory triazole compositions and methods for using same
FR2546520B1 (fr) * 1983-05-27 1985-08-30 Sanofi Sa Nouveaux composes antibiotiques derives des cephalosporines
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
HUP0000492A3 (en) * 1996-11-22 2000-06-28 Lilly Co Eli N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
CA2501803A1 (en) * 2002-10-09 2004-04-22 Pfizer Products Inc. Thiazole compounds for the treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
WO2004009565A3 (fr) 2004-04-08
CY1107903T1 (el) 2013-09-04
DK1525193T3 (da) 2008-04-28
JP2005538086A (ja) 2005-12-15
TW200413341A (en) 2004-08-01
AR040570A1 (es) 2005-04-13
ES2297198T3 (es) 2008-05-01
EP1525193A2 (de) 2005-04-27
EP1525193B1 (de) 2007-12-26
DE60318317D1 (de) 2008-02-07
US7291636B2 (en) 2007-11-06
US20080051436A1 (en) 2008-02-28
JP4680593B2 (ja) 2011-05-11
US7795289B2 (en) 2010-09-14
PT1525193E (pt) 2008-02-25
TWI313680B (en) 2009-08-21
WO2004009565A2 (fr) 2004-01-29
US20050182104A1 (en) 2005-08-18
DE60318317T2 (de) 2009-07-09
AU2003269018A1 (en) 2004-02-09
FR2842523A1 (fr) 2004-01-23

Similar Documents

Publication Publication Date Title
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
DE69926800D1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
ATE521598T1 (de) 5-phenylthiazol-derivate und ihre verwendung als pi3 kinase inhibitoren
IL173986A0 (en) 2-pyridone derivatives as netrophil elastase inhibitors and their use
DE60103974D1 (de) Gyrase-inhibitoren und ihre verwendung
DE60319951D1 (de) Aminocyclische substituierte pyrrolopyrimidinderivate und pyrrolopyridinderivate
DE602004019294D1 (de) Tetrahydronaphthalin- und harnstoffderivate
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
IS2504B (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
DE60308387D1 (de) Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
IS7749A (is) Pýrimídínafleiður og notkun þeirra sem CB2 beina
ATE382040T1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren
DE50313157D1 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
DE60321958D1 (de) Indazolderivate und ihre verwendung als crf antagonisten
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
ATE512148T1 (de) Pyrazolo- und imidazopyrimidinderivate
ATE308323T1 (de) Diaminothiazole und ihre anwendung als cdk4 inhibitoren
DE60037183D1 (de) Neue amidinbenzylamin-derivate und ihre verwendung als thrombin-inhibitoren
ATE353083T1 (de) Naphthyridin-derivate und ihre verwendung als fungizide
ATE277023T1 (de) Indanderivate und ihre verwendung als zelladhäsionsinihibitoren
ATE517098T1 (de) Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
EP1583528A4 (de) Nf-kb inhibitoren und ihre verwendungen
DE50313185D1 (de) 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1525193

Country of ref document: EP